Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center LAO
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Moffitt Cancer Center - Mckinley Campus
Tampa, Florida, United States
- Moffitt Cancer Center-International Plaza
Tampa, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- Haysmed
Hays, Kansas, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- the University of Kansas Cancer Center - Olathe
Olathe, Kansas, United States
- Mercy Hospital Pittsburg
Pittsburg, Kansas, United States
- Salina Regional Health Center
Salina, Kansas, United States
- University of Kansas Health System Saint Francis Campus
Topeka, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- University Health Truman Medical Center
Kansas City, Missouri, United States
- Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
- Wake Forest University at Clemmons
Clemmons, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Ut Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Dec 2019
- Primary completion
- 30 Oct 2023
- Completion
- 16 Apr 2027
- Last update posted
- 17 Jun 2026
- Registered enrollment
- 54
- Registry id
- NCT03872427
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.